Specifically, the role of infection-induced lung inflammation and injury is pivotal, indicating that developing MNK-specific inhibitors could advance drug development for ALI and offer new therapeutic strategies for its treatment [23,24]. The gene discussed is ATP7A; the disease is acute respiratory distress syndrome.